Apo-Metformin
Brand names,
Apo-Metformin
Analogs
Apo-Metformin
Brand Names Mixture
Apo-Metformin
Chemical_Formula
C10H13NO4
Apo-Metformin
RX_link
http://www.rxlist.com/cgi/generic2/methyl.htm
Apo-Metformin
fda sheet
Apo-Metformin
msds (material safety sheet)
Apo-Metformin
Synthesis Reference
No information avaliable
Apo-Metformin
Molecular Weight
211.215 g/mol
Apo-Metformin
Melting Point
300 oC
Apo-Metformin
H2O Solubility
1000 mg/L
Apo-Metformin
State
Solid
Apo-Metformin
LogP
-1.849
Apo-Metformin
Dosage Forms
Liquid for injection; Tablets for oral use (125 mg, 250 mg, or 500 mg)
Apo-Metformin
Indication
For use in the treatment of hypertension.
Apo-Metformin
Pharmacology
Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.
Apo-Metformin
Absorption
Absorption from the gastrointestinal tract is variable but averages approximately 50%.
Apo-Metformin
side effects and Toxicity
The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.
Apo-Metformin
Patient Information
No information avaliable
Apo-Metformin
Organisms Affected
Humans and other mammals